Type	Entity	Source evidence	Confidence	Extractor
gene	BCL6	“Histopathological analysis revealed dense dermal lymphoid infiltrate with a non-germinal centre phenotype (CD20+, MUM1+, BCL2+, BCL6+, CD10-).”	0.98	hgnc_dict_v1
phenotype	lymphoma	“Rare aggressive presentation of primary cutaneous diffuse large B-Cell lymphoma, leg type, in the upper arm with concurrent non-small cell lung cancer.”	0.98	phenotype_alias_lexicon_v2
gene	BCL2	“Histopathological analysis revealed dense dermal lymphoid infiltrate with a non-germinal centre phenotype (CD20+, MUM1+, BCL2+, BCL6+, CD10-).”	0.98	hgnc_dict_v1
phenotype	lung cancer	“Rare aggressive presentation of primary cutaneous diffuse large B-Cell lymphoma, leg type, in the upper arm with concurrent non-small cell lung cancer.”	0.98	phenotype_alias_lexicon_v2

PMID 40738056 | DOI 10.1016/j.prp.2025.156145 · Pathology, research and practice · 2025 · 3 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
gene	BCL6	“Particular focus is drawn to genetic mutations concerning Epstein-Barr virus (EBV)-related proteins, such as BCL6 and CREBBP, which are reported to cause disruptions in normal B cell formation and support aberrant cell growth.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“Molecular carcinogenesis in Hodgkin lymphoma: Interplay between B lymphocyte mutations and NF-κB pathway dysregulation.”	0.98	phenotype_alias_lexicon_v2
gene	CREBBP	“Particular focus is drawn to genetic mutations concerning Epstein-Barr virus (EBV)-related proteins, such as BCL6 and CREBBP, which are reported to cause disruptions in normal B cell formation and support aberrant cell growth.”	0.98	hgnc_dict_v1

PMID 38001281 | DOI 10.1007/s13353-023-00804-5 · Journal of applied genetics · 2024 · 4 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
gene	BCL6	“Genetic investigations, led by high-throughput sequencing, have unveiled recurrent mutations in genes such as MYC, BCL2, and BCL6, casting light on the underlying genetic chaos propelling DLBCL's aggressiveness.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.”	0.98	phenotype_alias_lexicon_v2
gene	MYC	“Genetic investigations, led by high-throughput sequencing, have unveiled recurrent mutations in genes such as MYC, BCL2, and BCL6, casting light on the underlying genetic chaos propelling DLBCL's aggressiveness.”	0.98	hgnc_dict_v1
gene	BCL2	“Genetic investigations, led by high-throughput sequencing, have unveiled recurrent mutations in genes such as MYC, BCL2, and BCL6, casting light on the underlying genetic chaos propelling DLBCL's aggressiveness.”	0.98	hgnc_dict_v1

PMID 34679437 | PMCID PMC8535125 | DOI 10.3390/diagnostics11101739 · Diagnostics (Basel, Switzerland) · 2021 · 7 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
gene	BCL6	“These genetic mutations are involved in epigenetic modification, ability to escape immunosurveillance, impaired BCL6 and NF-κβ signaling pathways and blocking terminal differentiation.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin's lymphoma (NHL), arising from different stages of B-cell differentiation whose pathogenesis involves miRNAs.”	0.98	phenotype_alias_lexicon_v2
gene	MYC	“Recently miRNAs were also identified to act either as oncogenes or tumor suppressors in DLBCL pathology by altering the expression levels of some of the known DLBCL related oncogenes. i.e., miR-155, miR-17-92 and miR-21 act as oncogenes by altering the expression levels of MYC, SHIP and FOXO1, respectively, conversely; miR-34a, mir-144 and miR-181a act as tumor suppressors by altering the expression levels of SIRT1, BCL6 and CARD11, respectively.”	0.98	hgnc_dict_v1
gene	FOXO1	“Recently miRNAs were also identified to act either as oncogenes or tumor suppressors in DLBCL pathology by altering the expression levels of some of the known DLBCL related oncogenes. i.e., miR-155, miR-17-92 and miR-21 act as oncogenes by altering the expression levels of MYC, SHIP and FOXO1, respectively, conversely; miR-34a, mir-144 and miR-181a act as tumor suppressors by altering the expression levels of SIRT1, BCL6 and CARD11, respectively.”	0.98	hgnc_dict_v1

PMID 32541138 | DOI 10.1159/000505715 · Acta haematologica · 2020 · 7 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
gene	BCL6	“Here, we describe a young adult patient with a novel combined germline PTPN11 and somatic NPM1, IDH1,and BCL6 mutations who presented with fatal AML.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“While mutations in the transcriptional repressor BCL6 are known to contribute to the pathogenesis of diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), its novel identification in this patient suggests an expanded role in aggressive AML.”	0.98	phenotype_alias_lexicon_v2
gene	PTPN11	“Germline mutations in PTPN11 are the most common cause of NS.”	0.98	hgnc_dict_v1
gene	NPM1	“Somatic mutations in NPM1 occur frequently in AML.”	0.98	hgnc_dict_v1

PMID 31285189 | PMCID PMC6616265 | DOI 10.1182/bloodadvances.2019000251 · Blood advances · 2019 · 3 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
gene	BCL6	“In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non-germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearrangements are associated with inferior outcomes.”	0.98	hgnc_dict_v1
phenotype	lymphoma	“In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non-germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearrangements are associated with inferior outcomes.”	0.98	phenotype_alias_lexicon_v2
gene	BCL2	“COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.”	0.98	hgnc_dict_v1